CRMI released its interim results, with a profit attributable to shareholders of HKD 4.609 million, a year-on-year decrease of 78.15%
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, China Regenerative Medicine released its interim results for the six months ending June 30, 2025. The group achieved revenue of HKD 27.391 million, a year-on-year decrease of 54.18%; the profit attributable to equity holders of the company was HKD 4.609 million, a year-on-year decrease of 78.15%; earnings per share were HKD 0.0151
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments